Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [31] Diabetes: how to manage chronic kidney disease
    Clements, Jennifer
    DRUGS IN CONTEXT, 2022, 11
  • [32] Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
    Agarwal, Rajiv
    Ruilope, Luis M.
    Ruiz-Hurtado, Gema
    Haller, Hermann
    Schmieder, Roland E.
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Lambelet, Marc
    Nowack, Christina
    Kolkhof, Peter
    Joseph, Amer
    Bakris, George L.
    JOURNAL OF HYPERTENSION, 2023, 41 (02) : 295 - 302
  • [33] Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Zhao, Li-Min
    Zhan, Ze-Lin
    Ning, Jie
    Qiu, Mei
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [34] Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    Agarwal, Rajiv
    Filippatos, Gerasimos
    Pitt, Bertram
    Anker, Stefan D.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Gebel, Martin
    Ruilope, Luis M.
    Bakris, George L.
    EUROPEAN HEART JOURNAL, 2022, 43 (06) : 474 - +
  • [35] Biomarkers of rapid chronic kidney disease progression in type 2 diabetes
    Looker, Helen C.
    Colombo, Marco
    Hess, Sibylle
    Brosnan, Mary J.
    Farran, Bassam
    Dalton, R. Neil
    Wong, Max C.
    Turner, Charles
    Palmer, Colin N. A.
    Nogoceke, Everson
    Groop, Leif
    Salomaa, Veikko
    Dunger, David B.
    Agakov, Felix
    McKeigue, Paul M.
    Colhoun, Helen M.
    KIDNEY INTERNATIONAL, 2015, 88 (04) : 888 - 896
  • [36] Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study
    Guo, Kaifeng
    Zhang, Lei
    Zhao, Fangya
    Lu, Junxi
    Pan, Pan
    Yu, Haoyong
    Bao, Yugian
    Chen, Haibing
    Jia, Weiping
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (05) : 803 - 810
  • [37] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    Grunberger, George
    Camp, Sarah
    Johnson, Jeremy
    Huyck, Susan
    Terra, Steven G.
    Mancuso, James P.
    Jiang, Zhi Wei
    Golm, Gregory
    Engel, Samuel S.
    Lauring, Brett
    DIABETES THERAPY, 2018, 9 (01) : 49 - 66
  • [38] Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
    Oiwa, Ako
    Hiwatashi, Dai
    Takeda, Teiji
    Miyamoto, Takahide
    Kawata, Iori
    Koinuma, Masayoshi
    Yamazaki, Masanori
    Komatsu, Mitsuhisa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (09) : 2203 - 2210
  • [39] Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes
    Rigalleau, V.
    Cougnard-Gregoire, A.
    Nov, S.
    Gonzalez, C.
    Maury, E.
    Lorrain, S.
    Gin, H.
    Barberger-Gateau, P.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (02) : 270 - 274
  • [40] Screening and Management Recommendations for Type 2 Diabetes in Women With Breast Cancer
    Scott, Laura
    Truong, Lan-Linh
    Houlden, Robyn L.
    Wijeratne, Don Thiwanka
    CANADIAN JOURNAL OF DIABETES, 2024, 48 (01) : 66 - 72